Aytu Biopharma (AYTU) Operating Leases (2019 - 2022)

Aytu Biopharma (AYTU) has 4 years of Operating Leases data on file, last reported at $2.4 million in Q1 2022.

• On a quarterly basis, Operating Leases fell 31.26% year-over-year to $2.4 million in Q1 2022; TTM through Mar 2022 was $2.4 million, a 31.26% decrease from a year earlier, with the FY2021 full-year figure at $2.6 million, up 261.93% from the prior year.
• Operating Leases for Q1 2022 stood at $2.4 million, down from $2.7 million in the prior quarter.
• Over the last five years, Operating Leases for AYTU reached as high as $3.5 million in Q1 2021 and fell as low as $211056.0 in Q4 2020.
• Historically, Operating Leases has averaged $1.5 million across 4 years, with a median of $804393.0 in 2020.
• Across the five-year window, Operating Leases plunged 39.72% in 2020 and surged 1186.86% in 2021, its largest moves.
• Year by year, Operating Leases stood at $291813.0 in 2019, then fell by 27.67% to $211056.0 in 2020, then jumped by 1186.86% to $2.7 million in 2021, then fell by 11.41% to $2.4 million in 2022.
• Per Business Quant data, the three most recent Operating Leases figures were $2.4 million in Q1 2022, $2.7 million in Q4 2021, and $2.8 million in Q3 2021.